Pharma channel feed

Gilead spot­lights its on­col­o­gy work with first fo­cused brand­ing cam­paign

Last year
Marketing

House Re­pub­li­cans threat­en to sub­poe­na FDA over Covid re­search doc­u­ments

Last year
FDA+

Madri­gal builds on liv­er dis­ease aware­ness cam­paigns as it awaits FDA de­ci­sion on NASH drug resme­tirom

Last year
Marketing

No­vo in­vests $6B+ to ex­pand man­u­fac­tur­ing fa­cil­i­ties as de­mand for We­govy sky­rock­ets

Last year
Cell/Gene Tx
Manufacturing

How the price of Lil­ly's weight man­age­ment drug could fu­el its ri­val­ry with No­vo Nordisk

Last year

ADF asks SCO­TUS not to take up mifepri­s­tone case as Dan­co, DOJ say ar­gu­ments don't hold up

Last year
FDA+
Law

Ot­su­ka TV and ban­ner ads for Rex­ul­ti draw re­buke from FDA watch­dog

Last year
Marketing

As­traZeneca de­tails ex­pan­sive com­bo strat­e­gy for new oral GLP-1 as ex­ecs wa­ger obe­si­ty mar­ket is ‘here to stay’

Last year

Mer­ck KGaA tem­pers 2023 sales ex­pec­ta­tions af­ter un­der­whelm­ing third-quar­ter per­for­mance

Last year

No­vavax’s trou­bles con­tin­ue as Covid vac­cine mak­er plans an­oth­er $300M+ in cost-cut­ting

Last year
People

Take­da scores FDA ap­proval for $400M col­orec­tal can­cer ther­a­py

Last year
FDA+

As­traZeneca spot­lights bis­pecifics in can­cer as it rais­es guid­ance, while prun­ing rare dis­ease pipeline

Last year
R&D

Mer­ck KGaA’s Baven­cio no longer 'alone' in blad­der can­cer mar­ket, but growth op­por­tu­ni­ty re­mains

Last year

Sanofi CEO re­it­er­ates R&D bet is best long-term ap­proach, ad­dress­es probe on mar­ket ma­nip­u­la­tion al­le­ga­tions

Last year
People

No­vo Nordisk to dis­con­tin­ue long-act­ing in­sulin Lev­emir next year amid in­com­ing 65% price cut

Last year

FDA watch­dog ad­mon­ish­es Evofem for mar­ket­ing brochure for its con­tra­cep­tive Phexxi

Last year
FDA+
Marketing

Te­va says it's ac­tive­ly search­ing for late-stage pro­grams in next phase of growth strat­e­gy

Last year

Mod­er­na de­buts first Spike­vax brand cam­paign with light­heart­ed tone to ‘nor­mal­ize’ Covid vac­ci­na­tions

Last year
Marketing

FDA ap­proves an un­brand­ed ver­sion of megablock­buster Hu­mi­ra, but Ab­b­Vie says it won't 'cur­rent­ly' launch

Last year
FDA+

Gilead’s HIV sales hit $4.7B in Q3, first six-month PrEP ap­proval planned in 2025

Last year

Sen­ate Fi­nance Com­mit­tee unan­i­mous­ly ad­vances PBM, Medicare Part D re­forms

Last year
FDA+

Up­dat­ed: Eli Lil­ly's tirzepatide breaks in­to obe­si­ty mar­ket with FDA ap­proval

Last year
FDA+

Bay­er to pull fol­lic­u­lar lym­phoma drug Aliqopa from US mar­ket in an­oth­er blow to PI3K in­hibitor space

Last year

Bio­gen CEO seeks 'aw­ful lot more col­lab­o­ra­tions' to beef up R&D as it launch­es post­par­tum de­pres­sion, Alzheimer's and ALS drugs

Last year
Deals
First page Previous page 90919293949596 Next page Last page
A service from the Financial Times